R. Blamey

发表

Ki67 immunostaining in primary breast cancer: pathological and clinical associations.

I. Ellis, N. Bouzubar, K. Walker, 1989, British Journal of Cancer.

Routine audit of breast fine needle aspiration (FNA) cytology specimens and aspirator inadequate rates

I. Ellis, R. Blamey, S. Pinder, 1997, Cytopathology : official journal of the British Society for Clinical Cytology.

Expression of luminal and basal cytokeratins in human breast carcinoma

I. Ellis, S. Pinder, J. Robertson, 2004, The Journal of pathology.

A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks

G. Ball, I. Ellis, R. Rees, 2010, Breast Cancer Research and Treatment.

The primary use of endocrine therapies.

A. Howell, M. Dowsett, J. Robertson, 1998, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

The significance of p53 autoantibodies in the serum of patients with breast cancer.

I. Ellis, J. Robertson, R. Blamey, 1996, Anticancer research.

Digital imaging improves upright stereotactic core biopsy of mammographic microcalcifications.

I. Ellis, S. Pinder, R. Blamey, 2000, Clinical radiology.

Pathological-radiological correlations in benign lesions excised during a breast screening programme.

I. Ellis, L. Yeoman, S. Pinder, 1994, Clinical radiology.

The Role of Blood Tumor Marker Measurement (Using a Biochemical Index Score and C-Erbb2) in Directing Chemotherapy in Metastatic Breast Cancer

S. Pinder, R. Blamey, S. Pinder, 2000, The International journal of biological markers.

C-erbB2 expression predicts response to preoperative chemotherapy for locally advanced breast cancer.

I. Ellis, R. Blamey, R. Nicholson, 1998, Anticancer research.

Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy.

M. Williams, R. Blamey, R. Nicholson, 1989, European journal of cancer & clinical oncology.

Ki67 immunoreactivity in breast carcinoma: relationships to prognostic variables and short term survival.

I. Ellis, C. Elston, R. Blamey, 1992, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

A comparison outcome of male breast cancer with female breast cancer.

I. Ellis, R. Blamey, R. Blamey, 1997, American journal of surgery.

Potential for cost economies in guiding therapy in patients with metastatic breast cancer.

R. Blamey, J. Robertson, D. Whynes, 1995, British Journal of Cancer.

The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer.

R. Blamey, K. Cheung, J. Robertson, 1997, European journal of cancer.

Oestrogen and Progesterone Receptors as Prognostic Variables in Hormonally Treated Breast Cancer

R. Blamey, R. Nicholson, J. Robertson, 1996, The International journal of biological markers.

Prospective assessment of the role of five tumour markers in breast cancer

A. Howell, J. Robertson, R. Blamey, 2005, Cancer Immunology, Immunotherapy.

Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer.

J. Robertson, R. Blamey, J. Robertson, 1999, European journal of cancer.

Locally advanced breast cancer: long-term results of a randomized trial comparing primary treatment with tamoxifen or radiotherapy in post-menopausal women.

R. Blamey, R. Nicholson, J. Robertson, 1996, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Pre-treatment serum levels of tumour markers in metastatic breast cancer: a prospective assessment of their role in predicting response to therapy and survival.

R. Blamey, J. Robertson, R. Blamey, 1995, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Objective measurement of therapeutic response in breast cancer using tumour markers.

A. Howell, R. Blamey, J. Robertson, 1991, British Journal of Cancer.

Assessment of four monoclonal antibodies as serum markers in breast cancer.

A. Howell, J. Robertson, R. Blamey, 1990, European journal of cancer.

Pleural effusion in breast cancer: a review of the Nottingham experience.

R. Blamey, J. Robertson, A. Banerjee, 1994, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

C 35 overexpression defines subsets of human breast cancer and its immunoreceptor tyrosine-based activation motif represents a novel treatment target

R. Coombes, R. Blamey, D. Soria, 2022 .

Continuous chemotherapy in responsive metastatic breast cancer: a role for tumour markers?

R. Blamey, L. Jackson, S. Chan, 1993, British Journal of Cancer.

Serum tissue polypeptide specific antigen (TPS) in breast cancer patients: comparison with CA 15.3 and CEA.

R. Blamey, J. Robertson, P. Willsher, 1995, Anticancer research.

Serological monitoring of advanced breast cancer treated by systemic cytotoxic using a combination of ESR, CEA, and CA 15.3: fact or fiction?

R. Blamey, L. Jackson, S. Chan, 1991, Disease markers.

P-glycoprotein expression in locally advanced breast cancer treated by neoadjuvant chemotherapy.

I. Ellis, C. Elston, R. Blamey, 1992 .

Epithelial mucin core antigen (EMCA) in assessing therapeutic response in advanced breast cancer--a comparison with CA15.3.

R. Blamey, M. Price, C. Selby, 1993, British Journal of Cancer.

ADJUVANT CHEMOTHERAPY FOR BREAST CANCER

R. Blamey, 1979, The Lancet.

Effect of LHRH agonist, Zoladex, on ovarian histology

C. Elston, R. Blamey, J. Robertson, 1988, The British journal of surgery.

Audit of a conservative management policy of the axilla in elderly patients with operable breast cancer.

R. Blamey, J. Robertson, P. Willsher, 1997, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

A one-year audit of 255 operable breast cancers.

R. Blamey, J. Robertson, A. Mitchell, 1997, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Incidence of intramammary nodes in completion mastectomy specimens after axillary node sampling: implications for breast conserving surgery.

I. Ellis, R. Blamey, J. Robertson, 2008, Breast.

Paget's disease of the nipple

I. Ellis, R. Blamey, C. Elston, 1991, The British journal of surgery.

Thymidine kinase in breast cancer.

R. Blamey, J. Robertson, K. O’Neill, 1990, British Journal of Cancer.

Weekly low dosage epirubicin in advanced breast cancer.

R. Blamey, J. Robertson, L. Jackson, 1990, European journal of cancer.

A randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-up.

I. Ellis, S. Pinder, R. Blamey, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Omental transposition flap for gross locally recurrent breast cancer.

R. Blamey, K. Cheung, J. Robertson, 1997, The Australian and New Zealand journal of surgery.

Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long‐term follow‐up

S. Pinder, C. Elston, R. Blamey, 1994, Histopathology.

A randomised trial of second-line hormone vs single agent chemotherapy in tamoxifen resistant advanced breast cancer.

J. Haybittle, R. Blamey, L. Jackson, 1992, British Journal of Cancer.

Phyllodes tumours of the breast: a clinicopathological review of thirty‐two cases

S. Pinder, C. Elston, R. Blamey, 1995, Histopathology.

Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma

S. Pinder, C. Elston, R. Blamey, 1995, Histopathology.

Methodology of immunohistological detection of oestrogen receptor in human breast carcinoma in formalin‐fixed, paraffin‐embedded tissue: a comparison with frozen section methodology

C. Elston, R. Blamey, R. Nicholson, 1993, Histopathology.

Prognostic significance of the DNA content of human breast cancer

I. Ellis, C. Elston, R. Blamey, 1987, The British journal of surgery.

Are Medullary Breast Cancers an Indication for BRCA1 Mutation Screening? A Mutation Analysis of 42 Cases of Medullary Breast Cancer

I. Ellis, S. Pinder, R. Blamey, 2004, Breast Cancer Research and Treatment.

Silver-stained nucleolar organiser region counts are of no prognostic value in primary breast cancer.

I. Ellis, R. Blamey, J. Robertson, 1992, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Germ line mutations associated with breast cancer susceptibility.

R. Blamey, R. Macmillan, P. Iau, 2001, European journal of cancer.

Cellular effects of tamoxifen in primary breast cancer

I. Ellis, R. Blamey, R. Nicholson, 1991, Breast Cancer Research and Treatment.

Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer.

A. Howell, M. Dowsett, R. Mansel, 1994, Cancer research.

Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma

I. Ellis, R. Blamey, R. Nicholson, 2004, British Journal of Cancer.

Neuroendocrine differentiation and prognosis in breast adenocarcinoma

I. Ellis, S. Pinder, C. Elston, 2002, Histopathology.

An immunohistochemical examination of the expression of E‐cadherin, α‐ and β/γ‐catenins, and α2‐ and β1‐integrins in invasive breast cancer

S. Pinder, C. Elston, R. Blamey, 1999, The Journal of pathology.

Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer.

R. Blamey, R. Nicholson, J. Robertson, 1992, British Journal of Cancer.

Detection of polymorphic epithelial mucins in the serum of systemic breast cancer patients using the monoclonal antibody, NCRC-11

R. W. Baldwin, J. Robertson, R. Blamey, 1990, Cancer Immunology, Immunotherapy.

Transforming Growth Factor-α and Endocrine Sensitivity in Breast Cancer

I. Ellis, J. Robertson, R. Blamey, 1994 .

Hormone sensitivity in breast cancer: influence of heterogeneity of oestrogen receptor expression and cell proliferation.

I. Ellis, N. Bouzubar, K. Walker, 1991, European journal of cancer.

Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer

A. Howell, R. Blamey, J. Robertson, 1995, The Lancet.

A randomised trial of mastectomy only versus tamoxifen for treating elderly patients with operable primary breast cancer-final results at 20-year follow-up.

R. Blamey, J. Robertson, K. Cheung, 2011, Critical reviews in oncology/hematology.

I. Ellis, S. Pinder, R. Blamey, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy.

I. Ellis, R. Blamey, R. Nicholson, 1995, British Journal of Cancer.

c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer

I. Ellis, R. Blamey, R. Nicholson, 1998, Oncogene.

C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators.

I. Ellis, S. Pinder, C. Elston, 1996, British Journal of Cancer.

Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity.

I. Ellis, R. Blamey, R. Nicholson, 1993, European journal of cancer.

Oestrogen-regulated genes in breast cancer: association of pLIV1 with response to endocrine therapy.

I. Ellis, J. Robertson, R. Blamey, 1998, British Journal of Cancer.

Combined goserelin and tamoxifen in premenopausal advanced breast cancer: duration of response and survival.

R. Blamey, R. Nicholson, J. Robertson, 1991, European journal of cancer.

Expression of tumour-associated antigens in breast cancer primary tissue compared with serum levels.

I. Ellis, C. Elston, R. Blamey, 1993, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Prognostic factors at the time of diagnosis of metastatic breast cancer.

R. Blamey, J. Robertson, 1998, British Journal of Cancer.

Locally advanced primary breast cancer: medium-term results of a randomised trial of multimodal therapy versus initial hormone therapy.

R. Blamey, J. Robertson, S. Tan, 2001, European journal of cancer.

High levels of allele loss at the FHIT and ATM genes in non-comedo ductal carcinoma in situ and grade I tubular invasive breast cancers.

I. Ellis, R. Blamey, M. Sibbering, 1996, Cancer research.

Confirmation of a prognostic index for patients with metastatic breast cancer treated by endocrine therapy

R. Blamey, J. Robertson, I. Ellis, 2005, Breast Cancer Research and Treatment.

Dietary patterns across the life course , mammographic density and implications for breast cancer : results from a British prospective cohort

G. Ball, R. Coombes, R. Blamey, 2018 .

C35 overexpression defines subsets of human breast cancer and its immunoreceptor tyrosine-based activation motif represents a novel treatment target

G. Ball, R. Coombes, R. Blamey, 2018 .

O 4 Suppression of the NF-κ B cofactor Bcl 3 inhibits mammary epithelial cell apoptosis and , in breast tumours , correlates with poor prognosis

G. Ball, R. Coombes, R. Blamey, 2008 .

Carcinoembryonic antigen immunocytochemistry in primary breast cancer

I. Ellis, C. Elston, R. Blamey, 1989, Cancer.

Sentinel node biopsy for breast cancer may have little to offer four-node-samplers. results of a prospective comparison study.

I. Ellis, R. Blamey, S. Pinder, 2001, European journal of cancer.

Predictors of response to second-line endocrine therapy for breast cancer

I. Ellis, S. Pinder, C. Elston, 1997, Breast Cancer Research and Treatment.

Mammographic size of ductal carcinoma in situ does not predict the presence of an invasive focus.

I. Ellis, S. Pinder, R. Blamey, 1999, European journal of cancer.

The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer.

A. Howell, J. Robertson, R. Blamey, 1999, European Journal of Cancer.

Continuous cytotoxics in responsive metastatic breast cancer: A role for tumour markers

R. Blamey, R. A. Badley, A. Dixon, 1992 .

Biological factors of prognostic significance in locally advanced breast cancer

R. Blamey, J. Robertson, I. Ellis, 2004, Breast Cancer Research and Treatment.

The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women.

J. Robertson, R. Blamey, 2003, European journal of cancer.

Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival.

K. Walker, R. Blamey, J. Robertson, 1990, British Journal of Cancer.

Influence of Pregnancy on the Time of Presentation of Primary Breast Cancer

M. Williams, K. Griffiths, C. Elston, 1986 .

Local recurrence after simple mastectomy

I. Ellis, R. Blamey, S. Pinder, 1994, The British journal of surgery.

Combined endocrine effects of LHRH agonist (Zoladex®) and tamoxifen (Nolvadex®) therapy in premenopausal women with breast cancer

K. Walker, R. Blamey, R. Nicholson, 1989, The British journal of surgery.

Locally advanced breast cancer: early results of a randomised trial of multimodal therapy versus initial hormone therapy.

R. Blamey, J. Robertson, L. Jackson, 1997, European journal of cancer.

O-91 Prognostic estimation: re-analysis of data from cases diagnosed in 1990–99 by Cox proportional hazards method

G. Ball, I. Ellis, A. Green, 2007 .

The assessment of multiple variables on breast carcinoma fine needle aspiration (FNA) cytology specimens: method, preliminary results and prognostic associations

H. E. Naylor, C. Elston, R. Blamey, 1995, Cytopathology : official journal of the British Society for Clinical Cytology.

Tissue factor A new independent prognostic marker in breast cancer

I. Ellis, R. Blamey, A. Kakkar, 1996 .

Node‐negative breast cancer prognosis and DNA ploidy

C. Elston, R. Blamey, I. Ellis, 1992, The British journal of surgery.

An evaluation of the cell cycle‐associated monoclonal antibody Ki‐S1 as a prognostic factor in primary invasive adenocarcinoma of the breast

C. Elston, R. Blamey, I. Ellis, 1995, The Journal of pathology.

Wide local excision with 10 mm clearance without radiotherapy for DCIS

I. Ellis, S. Pinder, R. Blamey, 2001 .

Occult regional lymph node metastases from breast carcinoma: Immunohistological detection with antibodies CAM 5.2 and NCRC‐11

R. Blamey, C. Elston, R. Blamey, 1991, The Journal of pathology.

Incidence of clinically significant lymphoedema as a complication following surgery for primary operable breast cancer.

R. Blamey, R. Macmillan, D. Morgan, 2003, European journal of cancer.

CYTOTOXIC CHEMOTHERAPY IN BREAST CANCER

R. Peto, R. Blamey, 1985, The Lancet.

Diagnosis of breast cancer with core-biopsy and fine needle aspiration cytology.

S. Pinder, C. Elston, R. Blamey, 1996, The Australian and New Zealand journal of surgery.

Clinical and histological predictors of contralateral breast cancer.

I. Ellis, R. Blamey, C. Elston, 1999, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Woman feels breast lump--surgeon cannot: the role of ultrasound in arbitration.

R. Blamey, R. Macmillan, A. Evans, 2004, European journal of cancer.

Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.

R. Blamey, R. Blamey, R. Sylvester, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long‐term follow‐up

R. Blamey, C. Elston, R. Blamey, 1992, Histopathology.

Does cosmetic outcome from treatment of primary breast cancer influence psychosocial morbidity?

L Fallowfield, R W Blamey, R. Blamey, 1999, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

The accuracy of breast ultrasound in the evaluation of clinically benign discrete, symptomatic breast lumps.

I. Ellis, R. Blamey, S. Pinder, 1998, Clinical radiology.

Confirmation of a prognostic index in primary breast cancer.

I. O. Ellis, I. Ellis, M. Williams, 1987, British Journal of Cancer.

A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples.

R W Blamey, R. Blamey, S. Pinder, 1995, Human pathology.

Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein

R. Blamey, M. Galea, I. Ellis, 1993 .

Association of gene variants in the TGF-beta signalling pathways with invasive breast cancer risk

G. Ball, R. Coombes, R. Blamey, 2008 .

Suppression of the NF-κ B cofactor Bcl 3 inhibits mammary epithelial cell apoptosis and , in breast tumours , correlates with poor prognosis

G. Ball, R. Coombes, R. Blamey, 2022 .